Daiichi Sankyo Company Yönetim

Yönetim kriter kontrolleri 4/4

Daiichi Sankyo Company CEO'su Sunao Manabe, Jun2019 tarihinde atandı, in görev süresi 5.42 yıldır. in toplam yıllık tazminatı ¥ 385.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 28.1% maaş ve 71.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0% ine doğrudan sahiptir ve bu hisseler € 5.23K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 3.9 yıldır.

Anahtar bilgiler

Sunao Manabe

İcra Kurulu Başkanı

JP¥385.0m

Toplam tazminat

CEO maaş yüzdesi	28.1%
CEO görev süresi	5.4yrs
CEO sahipliği	0.00001%
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Sunao Manabe'un ücretlendirmesi Daiichi Sankyo Company'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	JP¥250b
Jun 30 2024	n/a	n/a	JP¥229b
Mar 31 2024	JP¥385m	JP¥108m	JP¥201b
Dec 31 2023	n/a	n/a	JP¥186b
Sep 30 2023	n/a	n/a	JP¥148b
Jun 30 2023	n/a	n/a	JP¥147b
Mar 31 2023	JP¥401m	JP¥108m	JP¥109b
Dec 31 2022	n/a	n/a	JP¥59b
Sep 30 2022	n/a	n/a	JP¥63b
Jun 30 2022	n/a	n/a	JP¥51b
Mar 31 2022	JP¥341m	JP¥108m	JP¥67b
Dec 31 2021	n/a	n/a	JP¥94b
Sep 30 2021	n/a	n/a	JP¥87b
Jun 30 2021	n/a	n/a	JP¥79b
Mar 31 2021	JP¥170m	JP¥99m	JP¥76b
Dec 31 2020	n/a	n/a	JP¥71b
Sep 30 2020	n/a	n/a	JP¥116b
Jun 30 2020	n/a	n/a	JP¥118b
Mar 31 2020	JP¥197m	JP¥97m	JP¥129b
Dec 31 2019	n/a	n/a	JP¥149b
Sep 30 2019	n/a	n/a	JP¥114b
Jun 30 2019	n/a	n/a	JP¥113b
Mar 31 2019	JP¥165m	JP¥90m	JP¥93b

Tazminat ve Piyasa: Sunao 'nin toplam tazminatı ($USD 2.49M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 4.81M ).

Tazminat ve Kazançlar: Sunao 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sunao Manabe (70 yo)

5.4yrs

Görev süresi

JP¥385,000,000

Tazminat

Mr. Sunao Manabe, D.V.M, Ph D., had been President of Daiichi Sankyo Company, Limited since April 1, 2017 until April 01, 2023 and serves as its Chief Executive Officer since June 17, 2019 and serves as it...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sunao Manabe	Group CEO & Executive Chairperson	5.4yrs	JP¥385.00m	0.000010% € 5.2k
Hiroyuki Okuzawa	President	1.6yrs	JP¥252.00m	0% € 0
Takashi Fukuoka	Senior Managing Exec. Officer	2.4yrs	JP¥147.00m	0% € 0
Shoji Hirashima	Senior Managing Executive Officer	5.6yrs	JP¥166.00m	0% € 0
Koji Ogawa	Managing Ex. Officer	7.6yrs	Veri yok	Veri yok
Tomohiro Kodama	General Manager of Finance & Accounting Department	no data	Veri yok	Veri yok
Hiroto Kashiwase	Executive Officer & Head of Technology Division	no data	Veri yok	Veri yok
Naoto Tsukaguchi	Gen. Counsel	no data	Veri yok	Veri yok
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	less than a year	Veri yok	Veri yok
Kentaro Asakura	Vice President of Corporate Communications Department	no data	Veri yok	Veri yok
Marielle Cohard-Radice	Global Head of Development	no data	Veri yok	Veri yok
Akio Sakurai	Corporate Officer	3.6yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: D4S 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sunao Manabe	Group CEO & Executive Chairperson	10.4yrs	JP¥385.00m	0.000010% € 5.2k
Hiroyuki Okuzawa	President	3.4yrs	JP¥252.00m	0% € 0
Takashi Fukuoka	Senior Managing Exec. Officer	2.4yrs	JP¥147.00m	0% € 0
Shoji Hirashima	Senior Managing Executive Officer	4.4yrs	JP¥166.00m	0% € 0
Takashi Matsumoto	Managing Executive Officer	less than a year	Veri yok	0% € 0
Kazuaki Kama	Independent Outside Chairperson	5.4yrs	Veri yok	0% € 0
Yo Honma	Independent Outside Director	less than a year	Veri yok	Veri yok
Takaaki Nishii	Independent Outside Director	1.4yrs	Veri yok	0% € 0
Sawako Nohara	Independent Outside Director	5.4yrs	Veri yok	0% € 0
Kenji Sato	Chairman of Audit & Supervisory Board	5.4yrs	Veri yok	0% € 0
Yukiko Imazu	Outside Audit & Supervisory Board Member	6.4yrs	Veri yok	Veri yok
Yasuhiro Komatsu	Independent Outside Director	2.4yrs	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: D4S 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Daiichi Sankyo Company Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Recent updates

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Second quarter 2025 earnings released: EPS: JP¥32.20 (vs JP¥20.86 in 2Q 2024)

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO

Daiichi Sankyo Company, Limited to Report Q2, 2025 Results on Oct 31, 2024

IHH Healthcare Berhad Provides Update on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

European Medicines Agency Validates Type II Variation Application for Daiichi Sankyo Company, Limited's ENHERTU

New minor risk - Share price stability

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

First quarter 2025 earnings released: EPS: JP¥44.60 (vs JP¥29.74 in 1Q 2024)

Final dividend of JP¥30.00 announced

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Full year 2024 earnings released: EPS: JP¥105 (vs JP¥56.96 in FY 2023)

Daiichi Sankyo Company, Limited to Report Q1, 2025 Results on Jul 31, 2024

Now 21% overvalued after recent price rise

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Now 22% overvalued after recent price rise

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Upcoming dividend of JP¥30.00 per share

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Investor sentiment improves as stock rises 17%

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Third quarter 2024 earnings released: EPS: JP¥34.71 (vs JP¥14.81 in 3Q 2023)

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab

Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024

Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc

IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

New major risk - Earnings quality

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş